Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?
PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.
Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance
MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.
Why Veracyte’s Medicare win for TrueMRD could reshape bladder cancer recurrence monitoring
MRD testing has payer momentum, but clinical adoption is tougher. Veracyte’s TrueMRD Medicare win puts bladder cancer monitoring in focus.